The hearing aid sector has huge potential because only 20% of those who could benefit use them, said Lukas Braunschweiler, CEO of Sonova.
Biotech stocks may or may not be in a bubble, but investors are definitely worried about sky-high valuations.
Saudi Arabia says its oil production is near an all time high of around 10 million barrels of crude oil per day
That isn't the time you want to be buying or hedging out against a long dollar position.
Amgen last generated a long-term overbought condition on the Dec. 9 close of $169.39, and the shares then fell 13% to a Feb. 4 low of $147.42.
Stocks gave back all gains in the final minutes of Monday's session, resistant to move higher even as a dive in the U.S. dollar corralled crude oil prices higher.
Big pharmaceuticals companies are expected to unveil lots of promising drug therapies in 2015 - specifically drugs that could make billions in sales within five years.
2015 is turning into an epic year for deals. Owning the stock of a likely takeover candidate can result in tidy profits. Jim Cramer names 19 companies to watch.
AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?
Aduro is expected to IPO in early April. Advaxis, the other Listeria-based immunotherapy, will be a direct beneficiary as a result of the exposure from Aduro's IPO.
The markets were trading narrowly mixed in midday trading Monday with the S&P 500 and Dow Jones Industrial Average moving higher, while the Nasdaq slipped.
ImmunoGen (IMGN) shares are climbing on a licensing agreement with Takeda Pharmaceutical (TKPYY).
After a huge rally on Friday, U.S. markets opened mixed on Monday.
Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.
Potatoes that won't bruise and apples that won't brown are a step closer to grocery store aisles.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV